TM2D2

Across TCGA pan-cancer cohorts, TM2D2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TM2D2 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TM2D2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TM2D2 expression acts as an unfavorable survival marker.

LUAD, UCEC, and GBM are the cancer types where TM2D2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.315	1.000	<.001	29	view →
UCEC	DFS	Median	All	0.725	1.000	.036	4	view →
GBM	DFS	Quartile	All	0.232	0.854	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TM2D2–LUAD (OS)

Open the LUAD breakdown →